Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GeoVax Labs ( (GOVX) ) has shared an update.
GeoVax Labs on February 13, 2026 entered into agreements for a registered direct offering of common stock and pre-funded warrants, alongside a concurrent private placement of Series A-1 and A-2 common warrants, raising gross proceeds of about $1 million. The deal, which closed on February 17, 2026, yielded approximately $865,000 in net proceeds earmarked for working capital and general corporate purposes, including advancing its pipeline of vaccine and immunotherapy candidates.
The company issued 402,000 shares and pre-funded warrants for 30,902 shares at $2.31 per share or equivalent, and granted a total of 865,804 unregistered common warrants at the same exercise price, while agreeing to certain issuance restrictions and a 12-month ban on variable-rate financings. GeoVax also amended existing July 2025 investor warrants for 236,000 shares, cutting the exercise price from $4.35 to $2.31 and aligning exercisability with future shareholder approval, a move that supports investor participation but may increase future equity dilution for existing shareholders.
The most recent analyst rating on (GOVX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on GeoVax Labs stock, see the GOVX Stock Forecast page.
Spark’s Take on GOVX Stock
According to Spark, TipRanks’ AI Analyst, GOVX is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, large losses, and sustained cash burn) and bearish technicals (below key moving averages with negative momentum). The main offset is the earnings-call catalyst around an expedited EMA development pathway and partnership interest, while valuation signals are limited due to negative earnings and no stated dividend.
To see Spark’s full report on GOVX stock, click here.
More about GeoVax Labs
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and immunotherapies for solid tumor cancers. Its lead programs include GEO-CM04S1, a next-generation COVID-19 vaccine in multiple Phase 2 trials targeting immunocompromised and healthy patients, and Gedeptin, an oncolytic gene-directed therapy for advanced head and neck cancers.
The company is also advancing a Mpox and smallpox vaccine that it expects to move directly into Phase 3, supported by a broad intellectual property portfolio and worldwide rights to its technologies and product candidates. GeoVax focuses on leveraging its platform to address unmet medical needs in both infectious disease prevention and oncology treatment.
Average Trading Volume: 143,950
Technical Sentiment Signal: Sell
Current Market Cap: $2.91M
For an in-depth examination of GOVX stock, go to TipRanks’ Overview page.